Description of the Outcomes of Prior Authorization of Palivizumab for Prevention of Respiratory Syncytial Virus Infection in a Managed Care Organization

BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of upper and lower respiratory tract infections in infants and young children. Most children are exposed to the virus before they are 2 years old and experience such symptoms as cough, fever, and irritability. In a select population...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Brieana C., Roylance, Derek, Mitchell, Matthew P., Patel, Sushma M., Cannon, H. Eric, Done, Jeffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437541/
https://www.ncbi.nlm.nih.gov/pubmed/20044843
http://dx.doi.org/10.18553/jmcp.2010.16.1.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437541/
https://www.ncbi.nlm.nih.gov/pubmed/20044843
http://dx.doi.org/10.18553/jmcp.2010.16.1.15

Ejemplares similares